LifeSci Capital Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)
LifeSci Capital's Sam Slutsky reaffirms a Buy rating on Olema Pharmaceuticals with a $39.00 price target. Slutsky, a 5-star analyst with a 34.9% average return, focuses on healthcare stocks. The analyst consensus for Olema is a Strong Buy with a $36.83 average price target.
In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Olema Pharmaceuticals, with a price target of $39.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
According to TipRanks, Slutsky is a 5-star analyst with an average return of 34.9% and a 49.65% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Cogent Biosciences, and Olema Pharmaceuticals.
Currently, the analyst consensus on Olema Pharmaceuticals is a Strong Buy with an average price target of $36.83.
